Hi everyone,
After 3.5 years of positive response on Ibrance/Letrozole, my wife has seen some progression--so yesterday, she began a new clinical trial (ACT16105) which is a Phase II trial of SAR439859, a Sanofi compound. From my (limited!) understanding, this is an attempt to develop an oral Selective Estrogen Receptor Degrader (SERD) that acts somewhat like Faslodex/Fulvestrant--obviously without the intra-muscular injections. (Sorry if my explanation is not totally accurate, but that was the gist of my understanding!) It is being tested against traditional meds such as Fulvestrant, Anastrozole, Letrozole, Exemestane and Tamoxifen--but my wife was "randomized" into the SAR439859 so has already had a couple days of the pills--so far, so good as far as side effects.
I believe this trial is being undertaken at nine different locations, including here at Dana Farber in Boston, where my wife has been undergoing her treatment since diagnosis in March 2017.
Wondering if anyone else is involved in this trial, or any other trials (I am aware of a few others, although this seems quite new) involving SAR439859? Would be interested in any feedback from this group.
Thanks so much as always,
Dave
PS Those of us in parts of New England got a few inches of snow for Halloween Weekend!